The Mesothelioma Guide Blog

In 2020, the U.S. Food and Drug Administration (FDA) approved Opdivo and Yervoy for mesothelioma. The two immunotherapy drugs were approved as a first-line treatment option for...

Mesothelioma is a rare cancer diagnosed in approximately 2,500 people in the U.S. each year. The average survival is 12-18 months, and surgery can help people extend their...

Mesothelioma doctors believe that the best approach to treating the aggressive cancer known as mesothelioma is with multiple approaches. This strategy – called multimodal...

Scientists found a link between expression levels of a specific protein and survival of people with mesothelioma. According to research published in the medical journal Cancers,...

UPDATE (07/01/2024); This article was updated with information on how much each state receives in the Johnson & Johnson talc cancer settlement. The amounts for each state are...

There are three cell types of the rare cancer called mesothelioma, and sarcomatoid mesothelioma is the most aggressive of the three. The average survival for people diagnosed with...

Johnson & Johnson is again on the wrong end of an extraordinary mesothelioma lawsuit. The health and beauty conglomerate was hit with a $260 million verdict in a mesothelioma...

Update (12/02/2024): A Connecticut Superior Court judge increased the verdict to $22.5 million after adding $7.5 million in punitive damages in November 2024. The family of a man...

Update (09/18/2024): The FDA approved Keytruda as a first-line treatment of unresectable, malignant pleural mesothelioma in September 2024. Years after the U.S. Food and Drug...

The U.S. Food and Drug Administration (FDA) in May approved an immunotherapy for a deadly type of lung cancer. The treatment, called Imdelltra (generic name tarlatamab), is a...